| Hazard Information | Back Directory | [Uses]
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1]. | [in vivo]
Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) shows potent anti-tumor activity in MUC16-expressing human OVCAR-3 mouse xenograft models[3]. | Animal Model: | Female CB17 ICR severe combined immunodeficient mice, OVCAR-3/luc mouse xenografts[3] | | Dosage: | 2.8 mg/kg | | Administration: | IV, once weekly for 4 total doses | | Result: | Improved survival. |
| Animal Model: | Female CB17 ICR severe combined immunodeficient mice, OVCAR-3 tumors grown in the mammary fat pads[3] | | Dosage: | 2 mg/kg | | Administration: | IV, once weekly for 3 total doses | | Result: | Significantly decreased the tumor volume. |
| [References]
[1] Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers (Basel). 2020 Aug 9;12(8):2223. DOI:10.3390/cancers12082223
[2] Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124-2130. DOI:10.1093/annonc/mdw401
[3] Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67(10):4924-32. DOI:10.1158/0008-5472.CAN-06-4512 |
|
| Company Name: |
bioleaper
|
| Tel: |
4000880777 17585207275 |
| Website: |
www.bioleaper.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|